| Literature DB >> 34930542 |
George M Solomon1, Julianna Bailey2, James Lawlor2, Peter Scalia3, Gregory S Sawicki4, Christopher Dowd5, Kathryn A Sabadosa5, Aricca Van Citters3.
Abstract
BACKGROUND: During the COVID-19 pandemic, CF centers shifted to a telehealth delivery model. Our study aimed to determine how people with CF (PwCF) and their families experienced telehealth and assessed its quality and acceptability for future CF care.Entities:
Keywords: COVID-19; Cystic Fibrosis; Experience of Care; Healthcare Utilization; Telehealth
Mesh:
Year: 2021 PMID: 34930542 PMCID: PMC8683126 DOI: 10.1016/j.jcf.2021.09.005
Source DB: PubMed Journal: J Cyst Fibros ISSN: 1569-1993 Impact factor: 5.482
Fig. 1Ease of Use and Quality Perceptions of Telehealth. A. Overall summary of ease of use data. B. Most common reasons for respondents’ poor perception of ease of use. C. Overall respondents’ perceptions of quality of telehealth.
Fig. 2Ranked Responses for Benefits and Limitations of Telehealth. A. Ranked responses for top benefits of telehealth among respondent's who viewed telehealth of high quality. B. Ranked responses of limitations for respondents who felt that telehealth was of poorer quality than in-person care.
Fig. 3Summary of Respondents’ Desire for Future telehealth. A. Distribution of responses regarding strongest desire for telehealth in future CF care. B. The desire for telehealth is significantly influenced by respondents’ perceptions of quality of telehealth (p<0.05). C. Distribution of responses of preference for mix of telehealth and in-person care in future CF care.
What changes would need to be made to telehealth for you to give it a higher rating?a
| Telehealth about the same or better than in person (n=102) | Telehealth somewhat or much worse than in person (n=101) | Total (n=203) | ||||
| Measurement and testing | 38 | 37% | 61 | 58% | 99 | 49% |
| Physical exam | 12 | 12% | 29 | 27% | 41 | 20% |
| Pulmonary function testing (in person) | 11 | 11% | 25 | 24% | 36 | 18% |
| Sputum/throat culture | 13 | 13% | 22 | 21% | 35 | 17% |
| Pulmonary function testing (remote) | 7 | 7% | 7 | 7% | 14 | 7% |
| Labs/imaging | 3 | 3% | 10 | 9% | 13 | 6% |
| Testing: Remote | 4 | 4% | 6 | 6% | 10 | 5% |
| Weight/height | 3 | 3% | 4 | 4% | 7 | 3% |
| Testing: In person | 0 | 0% | 6 | 6% | 6 | 3% |
| Care delivered via in-person visits | 26 | 27% | 19 | 18% | 45 | 22% |
| Care delivered via telehealth | 13 | 13% | 7 | 7% | 26 | 13% |
| Criteria for appropriateness of telehealth visit | 8 | 8% | 4 | 4% | 12 | 6% |
| Care delivered via mix of telehealth and in-person clinic visits | 3 | 3% | 3 | 3% | 6 | 3% |
| Multidisciplinary care team/provider | 9 | 9% | 10 | 9% | 19 | 9% |
| Communication/relationships | 7 | 7% | 10 | 9% | 17 | 8% |
| Care quality (unspecified) | 5 | 5% | 6 | 6% | 11 | 5% |
| Preparation for visit | 1 | 1% | 8 | 8% | 9 | 4% |
| Lack of time/inefficiency | 2 | 2% | 5 | 5% | 7 | 3% |
| Convenience | 2 | 2% | 3 | 3% | 5 | 2% |
Responses are limited to PwCF that responded with an 8 or lower to the following question: “On a scale from 0-9, please indicate your desire for future telehealth visits?” (n=204 of 308 respondents). The sample size was further reduced by 1 PwCF that did not respond to the question regarding quality of telehealth.
Patient perspectives on the changes in CF care that have occurred since the coronavirus/COVID-19 pandemic.
| What would you/your child like to see continued in the future? (n=288) | What would you/your child like to see changed in the future? (n=288) | |||
|---|---|---|---|---|
| Care delivery model | 174 | 61% | 53 | 18% |
| Care delivered via telehealth | 114 | 40% | 22 | 8% |
| Care delivered via mix of telehealth and in-person clinic visits | 40 | 14% | 15 | 5% |
| Care delivered via in-person clinic visit | 21 | 7% | 14 | 5% |
| Criteria for appropriateness of telehealth visit | 25 | 9% | - | - |
| Measurement and testing | 27 | 10% | 49 | 17% |
| Safety/infection prevention | 33 | 12% | 6 | 2% |
| Care logistics | 32 | 11% | 17 | 6% |
| Quality of care | 24 | 9% | 27 | 9% |
| Insurance/co-pay | 4 | 1% | 5 | 2% |
| Technology for telehealth | 2 | 1% | 5 | 2% |
| Research/treatment development | 1 | 0% | 6 | 2% |
| Other (e.g., COVID-19, mental health, social connection) | 17 | 6% | 20 | 7% |
| None/not applicable | 44 | 16% | 90 | 31% |